Fredrick Van Goor

Summary

Affiliation: Vertex Pharmaceuticals
Country: USA

Publications

  1. doi request reprint Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
    Fredrick Van Goor
    Vertex Pharmaceuticals Incorporated, 130 Waverly St, Cambridge, MA, United States Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, United States Electronic address
    J Cyst Fibros 13:29-36. 2014
  2. pmc Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
    Fredrick Van Goor
    Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 106:18825-30. 2009
  3. pmc Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
    Fredrick Van Goor
    Vertex Pharmaceuticals, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 108:18843-8. 2011
  4. doi request reprint Ivacaftor potentiation of multiple CFTR channels with gating mutations
    Haihui Yu
    Vertex Pharmaceuticals Incorporated, Cambridge, MA 02139, USA
    J Cyst Fibros 11:237-45. 2012
  5. ncbi request reprint Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
    Fredrick Van Goor
    Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, USA
    Am J Physiol Lung Cell Mol Physiol 290:L1117-30. 2006
  6. doi request reprint Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators
    Timothy Neuberger
    Vertex Pharmaceuticals Incorporated, San Diego, CA 92121, USA
    Methods Mol Biol 741:39-54. 2011
  7. pmc VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
    Hong Yu Ren
    Department of Cell Biology and University of North Carolina Cystic Fibrosis Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599 Vertex Pharmaceuticals, San Diego, CA 92121
    Mol Biol Cell 24:3016-24. 2013

Collaborators

  • Timothy Neuberger
  • Douglas M Cyr
  • Diane E Grove
  • Hong Yu Ren
  • Beth J Hoffman
  • Haihui Yu
  • Pattarawut Sopha
  • Oxana De La Rosa
  • Scott A Houck
  • James P Johnson
  • Chien Jung Huang
  • Bill Burton
  • Dong Cao
  • Art Urrutia
  • John Joubran
  • Sheila Seepersaud
  • Jennings Worley
  • Katherine Sussky

Detail Information

Publications7

  1. doi request reprint Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
    Fredrick Van Goor
    Vertex Pharmaceuticals Incorporated, 130 Waverly St, Cambridge, MA, United States Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, United States Electronic address
    J Cyst Fibros 13:29-36. 2014
    ..The aim of this in vitro study was to evaluate the effect of ivacaftor on mutant CFTR protein forms with defects in protein processing and/or channel function...
  2. pmc Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
    Fredrick Van Goor
    Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 106:18825-30. 2009
    ..These results support the hypothesis that pharmacological agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway...
  3. pmc Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
    Fredrick Van Goor
    Vertex Pharmaceuticals, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 108:18843-8. 2011
    ..VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR...
  4. doi request reprint Ivacaftor potentiation of multiple CFTR channels with gating mutations
    Haihui Yu
    Vertex Pharmaceuticals Incorporated, Cambridge, MA 02139, USA
    J Cyst Fibros 11:237-45. 2012
    ..The aim of this in vitro study was to determine whether ivacaftor potentiates mutant CFTR with gating defects caused by other CFTR gating mutations...
  5. ncbi request reprint Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
    Fredrick Van Goor
    Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, USA
    Am J Physiol Lung Cell Mol Physiol 290:L1117-30. 2006
    ..The CFTR-activating effects of the two mechanisms are additive and support the rationale of a drug discovery strategy based on rescue of the basic genetic defect responsible for CF...
  6. doi request reprint Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators
    Timothy Neuberger
    Vertex Pharmaceuticals Incorporated, San Diego, CA 92121, USA
    Methods Mol Biol 741:39-54. 2011
    ..It is expected that the pre-clinical testing of CFTR potentiators and correctors using epithelial cell cultures derived from CF patients will help to increase their likelihood of clinical efficacy...
  7. pmc VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
    Hong Yu Ren
    Department of Cell Biology and University of North Carolina Cystic Fibrosis Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599 Vertex Pharmaceuticals, San Diego, CA 92121
    Mol Biol Cell 24:3016-24. 2013
    ..These data suggest that the use of VX-809 in combination with an additional CFTR corrector that suppresses folding defects downstream of MSD1 may further enhance CFTR function in people with F508del-CFTR. ..